CGTLive’s Weekly Rewind – May 5, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Liso-cel Approved as Second-Line Treatment in LBCL by European Commission

The decision, which aligns with its indication in the US, was based on efficacy and safety results from Bristol Myers Squibb’s TRANSFORM clinical trial in forms of large B-cell lymphoma.

2. Bart P. Leroy, MD, PhD, on Improving Light Sensitivity, Quality of Life With Luxturna

The head of the Department of Ophthalmology at the Center for Medical Genetics, Ghent University Hospital, discussed the main takeaways of a post-marketing study on the gene therapy.

3. ICER Reports Sickle Cell Gene Therapy Cost Effective at $1.9 Million

The draft report was released shortly after the BLA submission of exa-cel was completed and shortly before submission of lovo-cel.

4. Raphaël Ognar on Developing CIR-NK Cells to Better Target Cancer Cells

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

5. Liso-cel Meets Primary End Point in Follicular and Mantle Cell Lymphoma Trials

Bristol Myers Squibb noted that in addition to meeting the ORR end point, both trials also met a key secondary CR rate end point.